Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Regulation of interleukin-6 gene expression by pro-inflammatory cytokines in a colon cancer cell line.
|
10903137 |
2000 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
IL-6 increased mildly (up to 220 pg/ml) following vector administration to skin and lung airways of normal individuals and of individuals with CF, and to muscle and liver metastasis of individuals with PVD and colon cancer, respectively.
|
12349828 |
2002 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
TGF-beta suppresses tumor progression in colon cancer by inhibition of IL-6 trans-signaling.
|
15485627 |
2004 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Growth hormone increased SHP-2/glycoprotein 130 binding and reduced interleukin 6-dependent STAT3 activation in the T84 human colon carcinoma and Jurkat human T-cell leukemia lines.
|
16012947 |
2005 |
Colon Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Both IL6 polymorphisms were associated with significant interaction with current use of aspirin/NSAIDs to alter risk of colon cancer: individuals with a C allele in either polymorphism who were current users of aspirin/NSAIDs had the lowest colon cancer risk.
|
17694420 |
2007 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we report evidence on the role of interleukin 6 (IL-6) in affecting pro-survival pathways in colon cancer progression, modulating the expression and the molecular interactions among the pro-apoptotic factor Bax, the DNA repair proteins Ku70/86 and Clusterin isoforms.
|
19177010 |
2009 |
Colon Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The most significant finding (nominal P = 0.0004; false discovery rate q = 0.037) was a combined genotype association across IKBKB SNP rs5029748 (1 or 2 variant alleles), IL6 rs1800797 (1 or 2 variant alleles), and NFKB1 rs4648110 (2 variant alleles) which conferred an ~80% decreased risk of colon cancer.
|
21129206 |
2010 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anchorage-independent growth and migration of colon cancer cells was also increased by IL-6 in a 5-azadeoxycytidine-sensitive manner.
|
20354000 |
2010 |
Colon Carcinoma
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Influence of IL-6-174 G/C polymorphism on IL-6 mRNA expression and sporadic colon cancer susceptibility was evaluated as well.
|
20132036 |
2010 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We used recombinant sgp130Fc protein and recently generated transgenic mice expressing high levels of sgp130Fc to discriminate between classic and trans-signaling in vivo, and demonstrated that IL-6 trans-signaling is critically involved in generation and maintenance of several inflammatory and autoimmune diseases including chronic inflammatory bowel disease, rheumatoid arthritis, peritonitis and asthma, as well as inflammation-induced colon cancer.
|
21145125 |
2011 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study used colon cancer cell lines to test the hypothesis that IL-6 and TNFα induce TNFR2 via STAT3 and/or NFκB.
|
21994466 |
2011 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Transcription factor NFATc2 controls the emergence of colon cancer associated with IL-6-dependent colitis.
|
22738913 |
2012 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interleukin-6 (IL-6) induced STAT3 activation is viewed as crucial for multiple tumor growth and metastasis, including colon cancer.
|
22750444 |
2012 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We treated the colon cancer cell line COGA-1A for 6, 12, and 24h with 1,25-dihydroxyvitamin D3 (1,25-D3), IL-6, TNFα, and with combinations of these compounds.
|
24120915 |
2014 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The effectiveness of an anti-human IL-6 receptor monoclonal antibody combined with chemotherapy to target colon cancer stem-like cells.
|
25625841 |
2015 |
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Interleukin-6 is up-regulated in colon cancer tissue at the transcriptional level and is significantly associated with increased risk of relapse.
|
25862884 |
2015 |
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Interleukin-1 Receptor Type 2 Acts with c-Fos to Enhance the Expression of Interleukin-6 and Vascular Endothelial Growth Factor A in Colon Cancer Cells and Induce Angiogenesis.
|
26209639 |
2015 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We determined whether RPTS influences the interleukin-6 (IL-6)/Janus kinase (JAK)-signal transducer and activator of transcription-3 (STAT3) apoptosis molecular pathway and looked for colon cancer-related signal transduction pathways or targets inducing apoptosis.
|
26125778 |
2015 |
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, cycling hypoxia-specific inflammatory phenotype, characterized by a simultaneous (baculoviral inhibitor of apoptosis repeat-containing 5)(low)/PTGS2(high)/ICAM-1(high)/IL-6(high)/IL-8(high) expression, is associated with a poor prognosis in human colon cancer.
|
25622900 |
2015 |
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
15-LOX-1 down-regulation was associated with IL-6 up-regulation in human colon cancer mucosa.
|
25713055 |
2015 |
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
MSI in colon cancer is linked to a significant increase of immunocompetent cells responsible for the antitumor activity - CD3(+), CD8(+), CD45RO(+), and T-bet(+) lymphocytes and decrease of inhibition factors such as Foxp3, IL-6, IL-17, and TGF-β.
|
27372860 |
2016 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Fermented Herbal Formulas KIOM-MA128 Ameliorate IL-6-Induced Intestinal Barrier Dysfunction in Colon Cancer Cell Line.
|
27980357 |
2016 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Anti-IL-6 therapeutics are available for treating colon cancer; however, they are expensive and induce negative side effects.
|
28193578 |
2017 |
Colon Carcinoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Notch, EGFR/ErbB, IL-6/sIL-6R) help control intestinal injury/regenerative responses and may drive intestinal inflammation and colon cancer initiation and progression.
|
28739265 |
2017 |
Colon Carcinoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
This analysis identified downregulation of MUC2 and overexpression of IL-6 in colon cancer but not in normal colon tissue, and this expression pattern was correlated with poor survival of colon cancer patients.
|
28725043 |
2017 |